当前位置： SCI文献检索 > BREAST CANCER RESEARCH AND TREATMENT期刊下所有文献 > Enumeration of circulating tumor cells in the blood of breast cancer patients after filtration enrichment: correlation with disease stage.

Enumeration of circulating tumor cells in the blood of breast cancer patients after filtration enrichment: correlation with disease stage.

Abstract：

:The biological and clinical significance of circulating tumor cells (CTC) in the peripheral blood of breast cancer patients is not known. To study this question, we used a direct visualization assay to correlate the number of CTC with disease stage and progression. The CTC were enriched from the nucleated cell fraction by filtration and enumerated visually following immunostaining with anti-cytokeratin 8 (CK8) antibody CAM 5.2. In mixing experiments, we achieved a limit of detection of 5 MCF7 cells per 5 ml of blood or 5 x 10(7) peripheral blood leukocytes (PBL). We did not detect CTC in any control subjects (0/20). In 131 breast cancer patients, we found a higher incidence of CTC in patients with distant metastatic 36/51 (71%) than those with node-positive 17/36 (47%) (p = 0.026), or node-negative 17/44 (39%) (p = 0.001) disease. The distribution of the highest numbers of CTC observed in individual patients by repeated sampling over time ranged from 1 to 700 per 5 ml of blood with a trend toward higher numbers in those with distant metastases. In comparison with previous studies of equal specificity, based on a similar absence of CTC in controls, we report a higher incidence of CTC in node-negative and node-positive patients, suggesting a more frequent detection of CTC by our approach. This higher incidence was achieved, in part, by repeated sampling of our study population over time. Our results support the concept that CTC can be detected and enumerated in peripheral blood and that this minimally invasive assay merits further evaluation as a potential prognostic indicator and marker of disease progression.

journal_name

Breast Cancer Res Treat

journal_title

Breast cancer research and treatment

authors

Kahn HJ,Presta A,Yang LY,Blondal J,Trudeau M,Lickley L,Holloway C,McCready DR,Maclean D,Marks A

doi

10.1023/B:BREA.0000036897.92513.72

subject

Has Abstract

pub_date

2004-08-01 00:00:00

pages

237-47

issue

3

eissn

0167-6806

issn

1573-7217

pii

5272126

journal_volume

86

pub_type

杂志文章

相关文献

BREAST CANCER RESEARCH AND TREATMENT文献大全
  • Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancer.

    abstract：:The AZURE trial is an ongoing phase III, academic, multi-centre, randomised trial designed to evaluate the role of zoledronic acid (ZOL) in the adjuvant therapy of women with stage II/III breast cancer. Here, we report the safety and tolerability profile of ZOL in this setting. Eligible patients received (neo)adjuvant...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,随机对照试验

    doi：10.1007/s10549-011-1429-y

    authors： Coleman R,Woodward E,Brown J,Cameron D,Bell R,Dodwell D,Keane M,Gil M,Davies C,Burkinshaw R,Houston SJ,Grieve RJ,Barrett-Lee PJ,Thorpe H

    更新日期：2011-06-01 00:00:00

  • Effects of exercise intervention in breast cancer patients: is mobile health (mHealth) with pedometer more effective than conventional program using brochure?

    abstract：PURPOSE:To investigate and compare the effects of mobile health (mHealth) and pedometer with conventional exercise program using a brochure on physical function and quality of life (QOL). METHODS:The study was a prospective, quasi-randomized multicenter trial where 356 patients whose cancer treatment had been terminat...

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章,多中心研究,随机对照试验

    doi：10.1007/s10549-016-4065-8

    authors： Uhm KE,Yoo JS,Chung SH,Lee JD,Lee I,Kim JI,Lee SK,Nam SJ,Park YH,Lee JY,Hwang JH

    更新日期：2017-02-01 00:00:00

  • Effects of toremifene (TOR) and tamoxifen (TAM) on serum lipids in postmenopausal patients with breast cancer.

    abstract：:This study clarified the difference in the effects on serum lipids between toremifene (TOR) and tamoxifen (TAM). To remove influencing factors, we investigated adjuvant therapy for hormone receptor-positive patients with breast cancer without lymph node metastasis. The subjects were 65 patients who were enrolled in a ...

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章,多中心研究,随机对照试验

    doi：10.1007/s10549-004-4384-z

    authors： Kusama M,Miyauchi K,Aoyama H,Sano M,Kimura M,Mitsuyama S,Komaki K,Doihara H

    更新日期：2004-11-01 00:00:00

  • A novel BRCA2 mutation that segregates with breast and prostate cancer in a Spanish family.

    abstract：:We report a novel germline 5369delATTT mutation in BRCA2 gene, detected in a 45-year-old woman with bilateral breast cancer. This deletion was also detected in her father with prostatic cancer and her sister with breast cancer. The mutation originates a premature stop at codon 1723 of BRCA2 protein and has not been do...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-009-0361-x

    authors： Salgado J,Aramendía JM,Gutierrez C,Gil C,Robles M,García-Foncillas J

    更新日期：2010-05-01 00:00:00

  • Hormone receptors and obesity in Japanese women with breast cancer.

    abstract：:An association between hormone receptors in primary breast cancer and obesity determined prior to mastectomy was investigated in 128 Japanese women. The following criteria for obesity were used: (1) weight greater than or equal to 60 kg (132 lbs), (2) weight kg/height cm-105 greater than or equal to 1.3, (3) weight lb...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/BF01805867

    authors： Kuno K,Fukami A,Hori M,Kasumi F

    更新日期：1981-01-01 00:00:00

  • PAM50 assay and the three-gene model for identifying the major and clinically relevant molecular subtypes of breast cancer.

    abstract：:It has recently been proposed that a three-gene model (SCMGENE) that measures ESR1, ERBB2, and AURKA identifies the major breast cancer intrinsic subtypes and provides robust discrimination for clinical use in a manner very similar to a 50-gene subtype predictor (PAM50). However, the clinical relevance of both predict...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-012-2143-0

    authors： Prat A,Parker JS,Fan C,Perou CM

    更新日期：2012-08-01 00:00:00

  • Central nervous system metastases in women after multimodality therapy for high risk breast cancer.

    abstract：BACKGROUND:Central nervous system (CNS) relapse is increasing in breast cancer. This increase may reflect altered failure patterns from adjuvant therapy, more effective systemic therapy with improved control in non-CNS sites, or a resistant breast cancer subtype. METHODS:To determine the factors associated with clinic...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-004-0999-3

    authors： Carey LA,Ewend MG,Metzger R,Sawyer L,Dees EC,Sartor CI,Moore DT,Graham ML

    更新日期：2004-12-01 00:00:00

  • Single nucleotide polymorphisms of the aromatase gene (CYP19A1), HER2/neu status, and prognosis in breast cancer patients.

    abstract：PURPOSE:Estrogen exposure is involved in both breast cancer susceptibility and the prognosis in patients with breast cancer. Aromatase is involved in the production of estrogens, and altered expression of it might be associated with the prognosis. The aim of this study was to examine the effect of single nucleotide pol...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-007-9822-2

    authors： Fasching PA,Loehberg CR,Strissel PL,Lux MP,Bani MR,Schrauder M,Geiler S,Ringleff K,Oeser S,Weihbrecht S,Schulz-Wendtland R,Hartmann A,Beckmann MW,Strick R

    更新日期：2008-11-01 00:00:00

  • Black-white differences in receipt and completion of adjuvant chemotherapy among breast cancer patients in a rural region of the US.

    abstract：:Recent breast cancer treatment studies conducted in large urban settings have reported racial disparities in the appropriate use of adjuvant chemotherapy. This article presents the first focused evaluation of black-white differences in receipt and completion of chemotherapy for breast cancer in a primarily rural regio...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-011-1916-1

    authors： Lipscomb J,Gillespie TW,Goodman M,Richardson LC,Pollack LA,Ryerson AB,Ward KC

    更新日期：2012-05-01 00:00:00

  • Diagnostic ability of different human milk fat globule antigens in breast cancer.

    abstract：:Human mammary epithelial antigens (HME-Ags) are released into the circulation by breast tumors and not by normal breast tissue (Proc. Natl. Acad. Sci. USA 74: 582-586, 1977). This characteristic made them valuable, together with other breast cancer related antigens later identified, to develop immunoassays useful in t...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/BF01806353

    authors： Ceriani RL,Blank EW,Rosenbaum EH,Ben Zeev D,Lowitz RS,Johansen L,Trujillo T

    更新日期：1990-05-01 00:00:00

  • Clinical/genetic features in hereditary breast cancer.

    abstract：:Patients from hereditary breast cancer-prone (HBC) families provide one of the most powerful and potentially cost effective models for cancer prevention and control. Paradoxically, this opportunity is often missed in the clinical practice setting due, in part, to inattention to the family history and/or lack of knowle...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/BF01810778

    authors： Lynch HT,Watson P,Conway TA,Lynch JF

    更新日期：1990-02-01 00:00:00

  • Re-interpretation of PAM50 gene expression as quantitative tumor dimensions shows utility for clinical trials: application to prognosis and response to paclitaxel in breast cancer.

    abstract：BACKGROUND:We recently showed PAM50 gene expression data can be represented by five quantitative, orthogonal, multi-gene breast tumor traits. These novel tumor 'dimensions' were superior to categorical intrinsic subtypes for clustering in high-risk breast cancer pedigrees, indicating potential to represent underlying g...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-018-05097-5

    authors： Camp NJ,Madsen MJ,Herranz J,Rodríguez-Lescure Á,Ruiz A,Martín M,Bernard PS

    更新日期：2019-05-01 00:00:00

  • PK-M2-mediated metabolic changes in breast cancer cells induced by ionizing radiation.

    abstract：PURPOSE:Radiotherapy (RT) constitutes an important part of breast cancer treatment. However, triple negative breast cancers (TNBC) exhibit remarkable resistance to most therapies, including RT. Developing new ways to radiosensitize TNBC cells could result in improved patient outcomes. The M2 isoform of pyruvate kinase ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-019-05376-9

    authors： Zhang L,Bailleul J,Yazal T,Dong K,Sung D,Dao A,Gosa L,Nathanson D,Bhat K,Duhachek-Muggy S,Alli C,Dratver MB,Pajonk F,Vlashi E

    更新日期：2019-11-01 00:00:00

  • Oral fluoropyrimidine may augment the efficacy of aromatase inhibitor via the down-regulation of estrogen receptor in estrogen-responsive breast cancer xenografts.

    abstract：:The present preclinical study was designed to evaluate a new combination therapy comprised of the aromatase inhibitor anastrozole (ANA) and the oral fluoropyrimidines, UFT and S-1 against the estrogen receptor (ER)-positive human breast cancer cell line MCF-7/Arom 14, which was stably transfected with the cDNA of huma...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-010-1141-3

    authors： Nukatsuka M,Saito H,Nakagawa F,Abe M,Uchida J,Shibata J,Matsuo K,Noguchi S,Kiniwa M

    更新日期：2011-07-01 00:00:00

  • Estrogen receptor alpha polymorphisms and postmenopausal breast cancer risk.

    abstract：BACKGROUND:The estrogen receptor alpha (ESR1) is a mediator of estrogen response in the breast. The most studied variants in this gene are the PvuII and XbaI polymorphisms, which have been associated to lower sensitivity to estrogen. We evaluated whether these polymorphisms were associated with breast cancer risk by me...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-007-9562-3

    authors： González-Zuloeta Ladd AM,Vásquez AA,Rivadeneira F,Siemes C,Hofman A,Stricker BH,Pols HA,Uitterlinden AG,van Duijn CM

    更新日期：2008-02-01 00:00:00

  • Macromolecular interstitial clearance, tumour vascularity, other prognostic factors and breast cancer survival.

    abstract：BACKGROUND:Clearance of large molecules from the interstitial space is an important function of lymphatics and is affected by local pathologic changes. OBJECTIVE:To determine if the clearance rate of interstitially injected albumin is correlated to tumour characteristics and outcome in women with invasive breast cance...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/a:1005749825449

    authors： Sterns EE,SenGupta S,Zee B

    更新日期：1997-01-01 00:00:00

  • Biomarker expression and St Gallen molecular subtype classification in primary tumours, synchronous lymph node metastases and asynchronous relapses in primary breast cancer patients with 10 years' follow-up.

    abstract：:Molecular profiles of asynchronous breast cancer metastases are of clinical relevance to individual patients' treatment, whereas the role of profiles in synchronous lymph node metastases is not defined. The present study aimed to assess individual biomarkers and molecular subtypes according to the St Gallen classifica...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-013-2617-8

    authors： Falck AK,Bendahl PO,Chebil G,Olsson H,Fernö M,Rydén L

    更新日期：2013-07-01 00:00:00

  • Eight-year update of a prospective study of wide excision alone for small low- or intermediate-grade ductal carcinoma in situ (DCIS).

    abstract：:Whether wide excision with margins ≥1 cm is sufficient treatment for small low- or intermediate-grade ductal carcinoma in situ (DCIS) is unclear. This is an updated analysis of a phase II, single-arm, prospective trial testing this hypothesis. A total of 158 patients with low- or intermediate-grade DCIS who underwent ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-013-2813-6

    authors： Wong JS,Chen YH,Gadd MA,Gelman R,Lester SC,Schnitt SJ,Sgroi DC,Silver BJ,Smith BL,Troyan SL,Harris JR

    更新日期：2014-01-01 00:00:00

  • A family-based genetic association study of variants in estrogen-metabolism genes COMT and CYP1B1 and breast cancer risk.

    abstract：:In this paper, we report findings from a family-based association study examining the association between polymorphisms in two key estrogen-metabolism genes CYP1B1 (codon 432 G --> C and codon 453 A --> G variants) and COMT (codon 158 G --> A variant) and female breast cancer. We conducted the study among 280 nuclear ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/B:BREA.0000025401.60794.68

    authors： Ahsan H,Chen Y,Whittemore AS,Kibriya MG,Gurvich I,Senie RT,Santella RM

    更新日期：2004-05-01 00:00:00

  • The neuronal guidance cue Slit2 induces targeted migration and may play a role in brain metastasis of breast cancer cells.

    abstract：:Cell migration is essential in many diverse processes ranging from embryonic development to wound healing and immune response. Cancer cells have recently been shown to utilize chemoattraction mechanisms mediated by chemokines and their respective receptors, e.g., the CXCL12/CXCR4 pathway normally found in leukocytes. ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-007-9504-0

    authors： Schmid BC,Rezniczek GA,Fabjani G,Yoneda T,Leodolter S,Zeillinger R

    更新日期：2007-12-01 00:00:00

  • Mutation analysis of the SLX4/FANCP gene in hereditary breast cancer.

    abstract：:SLX4 coordinates three structure-specific endonucleases in the DNA damage response. One subtype of Fanconi anaemia, FA-P, has recently been attributed to biallelic SLX4 gene mutations. To investigate whether monoallelic SLX4 gene defects play some role in the inherited component of breast cancer susceptibility, in thi...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-011-1681-1

    authors： Landwehr R,Bogdanova NV,Antonenkova N,Meyer A,Bremer M,Park-Simon TW,Hillemanns P,Karstens JH,Schindler D,Dörk T

    更新日期：2011-12-01 00:00:00

  • The use of atypical antipsychotics and the risk of breast cancer.

    abstract：:To determine whether atypical antipsychotics, when compared to typical antipsychotics, increase the risk of breast cancer. We conducted a retrospective cohort study using a nested case-control analysis within the United Kingdom General Practice Research Database population. We identified all female patients prescribed...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-011-1506-2

    authors： Azoulay L,Yin H,Renoux C,Suissa S

    更新日期：2011-09-01 00:00:00

  • Microsatellite genotyping reveals a signature in breast cancer exomes.

    abstract：:Genomic instability at microsatellite loci is a hallmark of many cancers, including breast cancer. However, much of the genomic variation and many of the hereditary components responsible for breast cancer remain undetected. We hypothesized that variation at microsatellites could provide additional genomic markers for...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-014-2908-8

    authors： McIver LJ,Fonville NC,Karunasena E,Garner HR

    更新日期：2014-06-01 00:00:00

  • Loss of heterozygosity at BRCA2 in a ductal carcinoma in situ and three invasive breast carcinomas in a family with a germline BRCA2 mutation.

    abstract：:We have examined a family with a germline BRCA2 mutation in three cases of invasive breast cancer and one case of ductal carcinoma in situ (DCIS). Loss of heterozygosity (LOH) has been demonstrated at the BRCA2 locus in all cases. This result may suggest that the germline mutation in BRCA2 is the initiating step of DC...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-004-9503-3

    authors： Thomassen M,Kruse TA,Olsen KE,Borg A,Gerdes AM

    更新日期：2004-10-01 00:00:00

  • Expression of pp32 gene family members in breast cancer.

    abstract：:The pp32 gene family consists of at least three closely related members, pp32, pp32r1 and pp32r2. In spite of a high degree of identity at the nucleotide level, pp32 functionally behaves as a tumor suppressor where as pp32r1 and pp32r2 are pro-oncogenic. The purpose of this pilot study was to determine pp32-related ex...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/a:1017919507109

    authors： Kadkol SS,El Naga GA,Brody JR,Bai J,Gusev Y,Dooley WC,Pasternack GR

    更新日期：2001-07-01 00:00:00

  • A nationwide epidemiologic study of breast cancer incidence following breast reduction surgery in a large cohort of Swedish women.

    abstract：:While it has been demonstrated that prophylactic mastectomy reduces breast cancer incidence among women at high risk, many women often consider this disfiguring surgery unacceptable. One alternative approach may be breast reduction surgery. In order to evaluate the long-term incidence of breast cancer following surgic...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-005-9099-2

    authors： Fryzek JP,Ye W,Nyrén O,Tarone RE,Lipworth L,McLaughlin JK

    更新日期：2006-05-01 00:00:00

  • Young adult breast cancer patients have a poor prognosis independent of prognostic clinicopathological factors: a study from the Japanese Breast Cancer Registry.

    abstract：PURPOSE:The aim of this study was to investigate whether young age at onset of breast cancer is an independent prognostic factor in patients from the Japanese Breast Cancer Registry, after adjustment of known clinicopathological prognostic factors. METHODS:Of the 53,670 patients registered between 2004 and 2006 and su...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-016-3984-8

    authors： Kataoka A,Iwamoto T,Tokunaga E,Tomotaki A,Kumamaru H,Miyata H,Niikura N,Kawai M,Anan K,Hayashi N,Masuda S,Tsugawa K,Aogi K,Ishida T,Masuoka H,Iijima K,Kinoshita T,Nakamura S,Tokuda Y

    更新日期：2016-11-01 00:00:00

  • Erratum to: PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy.

    abstract：:Erratum to: Breast Cancer Res Treat (2013),138:369–381,DOI 10.1007/s10549-012-2389-6. In the original publication of the article, the Fig. 4c and d were published erroneously. The revised Fig. 4 is given in this erratum. ...

    journal_title：Breast cancer research and treatment

    pub_type： 已发布勘误

    doi：10.1007/s10549-016-3752-9

    authors： Wander SA,Zhao D,Besser AH,Hong F,Wei J,Ince TA,Milikowski C,Bishopric NH,Minn AJ,Creighton CJ,Slingerland JM

    更新日期：2016-04-01 00:00:00

  • Generation of CD8+ cytotoxic T lymphocytes against breast cancer cells by stimulation with mammaglobin-A-pulsed dendritic cells.

    abstract：:Mammaglobin-A is exclusively expressed by breast cancer cells. Thus, mammaglobin-A-specific T cell immune responses may be useful for the design of new breast cancer-specific immunotherapies. We show herein that CD8+ T cells generated against recombinant mammaglobin-A-pulsed dendritic cells display a marked cytotoxic ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/a:1023323509888

    authors： Manna PP,Jaramillo A,Majumder K,Campbell LG,Fleming TP,Dietz JR,Dipersio JF,Mohanakumar T

    更新日期：2003-05-01 00:00:00

  • Tamoxifen metabolism is altered by simultaneous administration of medroxyprogesterone acetate in breast cancer patients.

    abstract：:We have measured the levels of tamoxifen and three of its metabolites in the blood of patients receiving tamoxifen alone or combination therapy with tamoxifen and medroxyprogesterone acetate. Our results indicate that addition of the progestogen significantly alters the metabolism of tamoxifen over a six-month period....

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1007/BF01833345

    authors： Reid AD,Horobin JM,Newman EL,Preece PE

    更新日期：1992-01-01 00:00:00